Cargando…
Genetic Testing at Diagnosis Has Prognostic Value in Patients with Chronic Lymphocytic Leukemia including at Early Stages
Chronic lymphocytic leukemia (CLL) has a variable clinical evolution, with some patients living treatment-free for decades while others require therapy shortly after diagnosis. In a consecutive series of 217 CLL patients, molecular biomarkers with prognostic value (IGHV status, TP53 mutations, and c...
Autores principales: | Suárez-Cabrera, Alexia, Fiallo-Suárez, Dolly Viviana, Stuckey, Ruth, Uroz-de la Iglesia, Marta Luna, Florido, Yanira, Lemes-Castellano, Angelina, Perera-Álvarez, Miguel Ángel, Luzardo-Henríquez, Hugo, de la Nuez, Haridian, Fernández-Caldas, Paula, de la Iglesia, Silvia, Gómez-Casares, María Teresa, Bilbao-Sieyro, Cristina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394282/ https://www.ncbi.nlm.nih.gov/pubmed/35892513 http://dx.doi.org/10.3390/diagnostics12081802 |
Ejemplares similares
-
Integration of molecular testing for the personalized management of patients with diffuse large B-cell lymphoma and follicular lymphoma
por: Stuckey, Ruth, et al.
Publicado: (2023) -
CALR mutation characterization in myeloproliferative neoplasms
por: Bilbao-Sieyro, Cristina, et al.
Publicado: (2016) -
Positive Impact of Eculizumab Therapy on Surgery for Budd-Chiari Syndrome in a Patient with Paroxysmal Nocturnal Hemoglobinuria and a Long-Term History of Thrombosis
por: De-la-Iglesia, Silvia, et al.
Publicado: (2016) -
Thrombotic Risk Detection in Patients with Polycythemia Vera: The Predictive Role of DNMT3A/TET2/ASXL1 Mutations
por: Segura-Díaz, Adrián, et al.
Publicado: (2020) -
PB1754: HOMOZYGOUS DELETION OF ETV6: EARLY T-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA OR PRECURSOR T-LYMPHOBLASTIC LYMPHOMA
por: Álvarez, Miguel Ángel Perera, et al.
Publicado: (2023)